- Home
- XP vs QGEN Comparison
XP vs QGEN Comparison
Compare XP & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | QGEN |
|---|---|---|
| Founded | 2001 | 1986 |
| Country | Cayman Islands | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.0B |
| IPO Year | 2019 | 1998 |
Fundamental Metrics
Financial Performance| Metric | XP | QGEN |
|---|---|---|
| Price | $18.88 | $43.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $23.17 | ★ $45.76 |
| AVG Volume (30 Days) | ★ 4.6M | 3.1M |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | 0.98% | ★ 7.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.00 | $8.18 |
| Revenue Next Year | $13.64 | $5.71 |
| P/E Ratio | ★ $11.42 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.80 | $32.53 |
| 52 Week High | $23.13 | $57.82 |
Technical Indicators
Market Signals| Indicator | XP | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 69.17 | 58.07 |
| Support Level | $18.50 | $41.14 |
| Resistance Level | $20.16 | $44.22 |
| Average True Range (ATR) | 0.62 | 1.09 |
| MACD | 0.24 | -0.07 |
| Stochastic Oscillator | 97.77 | 67.64 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission. Geographically, the company derives maximum revenue from Brazil and also has its presence in other countries.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).